{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444377781
| IUPAC_name = (6''R'',7''S'')-7-(((((2''S'')-2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
| image = Cefminox.svg
| width = 280

<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|cefminox}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = IM, IV

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 84305-41-9
| ATC_prefix = J01
| ATC_suffix = DC12
| ATC_supplemental = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1276342
| PubChem = 71141
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PW08Y13465
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07642
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 64286
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)CSC[C@H](C(=O)O)N)CSc3nnnn3C)C(=O)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = JSDXOWVAHXDYCU-VXSYNFHWSA-N


<!--Chemical data-->
| chemical_formula = 
| C=16 | H=21 | N=7 | O=7 | S=3 
| molecular_weight = 519.57 g/mol
}}

'''Cefminox''' ([[International Nonproprietary Name|INN]]) is a second-generation [[cephalosporin]] [[antibiotic]].<ref>{{Cite journal 
| doi = 10.1007/s150100070027 
| last1 = Torres | first1 = A. J. 
| last2 = Valladares | first2 = L. D. 
| last3 = Jover | first3 = J. M. 
| last4 = Sánchez-Pernaute | first4 = A. 
| last5 = Frías | first5 = J. 
| last6 = Carcas | first6 = A. J. 
| last7 = Coronel | first7 = P. 
| last8 = Ródenas | first8 = E. 
| last9 = Pérez-Balcabao | first9 = I. 
| last10 = Fernández-Roblas | first10 = R. 
| last11 = Moreno | first11 = M. 
| last12 = Balibrea | first12 = J. L. 
| title = Cefminox versus metronidazole plus gentamicin intra-abdominal infections: A prospective randomized controlled clinical trial 
| journal = Infection 
| volume = 28 
| issue = 5 
| pages = 318–322 
| year = 2000 
| pmid = 11073141
}}</ref><ref>Patentdocs: [http://www.faqs.org/patents/app/20110039288 Reaction Medium For Methicillin-Resistant Staphylococcus Aureus (Mrsa) Bacteria]</ref>

==Spectrum==
Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. The following represents MIC data for a few medically significant microorganisms.
* ''Clostridium difficile'': 2 - 4 µg/ml
* ''Escherichia coli'': 0.125 - 16 µg/ml
* ''Pseudomonas aeruginosa'': 256 µg/ml
<ref>http://www.toku-e.com/Assets/MIC/Cefminox%20sodium.pdf</ref>

==References==
{{reflist}}

{{Cell wall disruptive antibiotics}}

[[Category:Cephalosporin antibiotics]]
[[Category:Tetrazoles]]


{{antibiotic-stub}}